US 11,674,950 B2
Methods determining and treating cellular resistance to ADP-rtbosylating toxin
Andrew Lane, Needham, MA (US); and Jon Aster, Lexington, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
Appl. No. 16/756,545
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
PCT Filed Oct. 30, 2018, PCT No. PCT/US2018/058222
§ 371(c)(1), (2) Date Apr. 16, 2020,
PCT Pub. No. WO2019/089603, PCT Pub. Date May 9, 2019.
Claims priority of provisional application 62/579,583, filed on Oct. 31, 2017.
Prior Publication US 2021/0325368 A1, Oct. 21, 2021
Int. Cl. A61K 45/06 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01)
CPC G01N 33/5011 (2013.01) [A61K 45/06 (2013.01); G01N 33/57426 (2013.01)] 35 Claims
 
1. A method of treating a subject afflicted with a condition that is resistant to an IL3-conjugated diphtheria (IL3-DT) toxin comprising administering to the subject a therapeutically effective amount of the IL3-DT toxin in combination with a therapeutically effective amount of an agent that increases the copy number, amount, and/or activity of DPH1, thereby treating the subject afflicted with the condition that is resistant to the IL3-DT toxin.